Anti-trypanosomatid benzofuroxans and deoxygenated analogues: synthesis using polymer-supported triphenylphosphine, biological evaluation and mechanism of action studies.

Hybrid vinylthio-, vinylsulfinyl-, vinylsulfonyl- and vinylketo-benzofuroxans developed as anti-trypanosomatid agents, against Trypanosoma cruzi and Leishmania spp., have showed low micromolar IC(50) values. The synthetic route to access to these derivatives was an efficient Wittig reaction performed in mild conditions with polymer-supported triphenylphosphine (PS-TPP). Additionally, the benzofurozan analogues, deoxygenated benzofuroxans, were prepared using PS-TPP as reductive reagent in excellent yields. The trypanosomicidal and leishmanocidal activities of the benzofuroxan derivatives were measured and also some aspects of their mechanism of action studied. In this sense, inhibition of mitochondrial dehydrogenases activities, production of intra-parasite free radicals and cruzipain inhibition were studied as biological target for the anti-trypanosomatid identified compounds. The trypanosomicidal activity could be the result of both the parasite-mitochondrion function interference and production of oxidative stress into the parasite.

[1]  W. Souza.  Basic cell biology of Trypanosoma cruzi. , 2002 .

[2]  N. Galanti,et al.  Mode of action of natural and synthetic drugs against Trypanosoma cruzi and their interaction with the mammalian host. , 2007, Comparative biochemistry and physiology. Part A, Molecular & integrative physiology.

[3]  J. Castro,et al.  Toxic Side Effects of Drugs Used to Treat Chagas’ Disease (American Trypanosomiasis) , 2006, Human & experimental toxicology.

[4]  C. Musonda,et al.  The synthesis of parasitic cysteine protease and trypanothione reductase inhibitors. , 2003, Current Medicinal Chemistry.

[5]  V. Arán,et al.  Indazole N-oxide derivatives as antiprotozoal agents: synthesis, biological evaluation and mechanism of action studies. , 2006, Bioorganic & medicinal chemistry.

[6]  M. Bertinaria,et al.  Furoxan-, alkylnitrate-derivatives and related compounds as anti-trypanosomatid agents: mechanism of action studies. , 2008, Bioorganic & medicinal chemistry.

[7]  F. Mendizábal,et al.  Electrochemical and microsomal production of free radicals from 1,2,5-oxadiazole N-oxide as potential antiprotozoal drugs. , 2003, Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy.

[8]  G. Peluffo,et al.  1,2,5-Oxadiazole N-oxide derivatives and related compounds as potential antitrypanosomal drugs: structure-activity relationships. , 1999, Journal of medicinal chemistry.

[9]  L. Zhai,et al.  The antileishmanial activity of novel oxygenated chalcones and their mechanism of action. , 1999, The Journal of antimicrobial chemotherapy.

[10]  J. McKerrow,et al.  A Cysteine Protease Inhibitor Cures Chagas' Disease in an Immunodeficient-Mouse Model of Infection , 2007, Antimicrobial Agents and Chemotherapy.

[11]  R. Schirmer,et al.  Dithiol proteins as guardians of the intracellular redox milieu in parasites: old and new drug targets in trypanosomes and malaria-causing plasmodia. , 2005, Angewandte Chemie.

[12]  H. Cerecetto,et al.  Chemotherapy of Chagas' disease: status and new developments. , 2002, Current topics in medicinal chemistry.

[13]  S. Bräse,et al.  Efficient solid-phase synthesis of highly functionalized 1,4-benzodiazepin-5-one derivatives and related compounds by intramolecular aza-Wittig reactions. , 2005, Chemistry.

[14]  H. Cerecetto,et al.  Heteroarylnitrones as drugs for neurodegenerative diseases: synthesis, neuroprotective properties, and free radical scavenger properties. , 2008, Journal of medicinal chemistry.

[15]  D. Horn,et al.  A mechanism for cross-resistance to nifurtimox and benznidazole in trypanosomes , 2008, Proceedings of the National Academy of Sciences.

[16]  D. Sereno,et al.  Use of an enzymatic micromethod to quantify amastigote stage of Leishmania amazonensis in vitro , 1997, Parasitology Research.

[17]  A. Merlino,et al.  o-Nitroanilines as major metabolic products of anti-Trypanosoma cruzi 5-phenylethenylbenzofuroxans in microsomal and cytosolic fractions of rat hepatocytes and in whole parasitic cells , 2009, Xenobiotica; the fate of foreign compounds in biological systems.

[18]  A. Rojas de Arias,et al.  2H-benzimidazole 1,3-dioxide derivatives: a new family of water-soluble anti-trypanosomatid agents. , 2006, Journal of medicinal chemistry.

[19]  J. McKerrow,et al.  Cysteine Protease Inhibitors Cure an Experimental Trypanosoma cruzi Infection , 1998, Journal of Experimental Medicine.

[20]  Shyam Sundar,et al.  Visceral leishmaniasis: current status of control, diagnosis, and treatment, and a proposed research and development agenda. , 2002, The Lancet. Infectious diseases.

[21]  S. Ley,et al.  Development of a polymer bound Wittig reaction and use in multi-step organic synthesis for the overall conversion of alcohols to β-hydroxyamines , 1998 .

[22]  J. Cazzulo.  Proteinases of Trypanosoma cruzi: patential targets for the chemotherapy of Changas desease. , 2002, Current topics in medicinal chemistry.

[23]  J. McKerrow,et al.  Cysteine protease inhibitors as chemotherapy for parasitic infections. , 1999, Bioorganic & medicinal chemistry.

[24]  A. Denicola,et al.  Benzo[1,2-c]1,2,5-oxadiazole N-oxide derivatives as potential antitrypanosomal drugs. Part 3: Substituents-clustering methodology in the search for new active compounds. , 2005, Bioorganic & medicinal chemistry.

[25]  Ming Chen,et al.  Inhibition of Fumarate Reductase inLeishmania major and L. donovani by Chalcones , 2001, Antimicrobial Agents and Chemotherapy.

[26]  A. Merlino,et al.  In vivo studies of 5-arylethenylbenzofuroxans in acute murine models of Chagas' disease. , 2008, European journal of medicinal chemistry.

[27]  E. Barreiro,et al.  New potent 5-substituted benzofuroxans as inhibitors of Trypanosoma cruzi growth: quantitative structure-activity relationship studies. , 2005, Bioorganic & medicinal chemistry.

[28]  A. Dietz,et al.  Microbiological production of 5-azacytidine. I. Production and biological activity. , 1966, Antimicrobial agents and chemotherapy.

[29]  J. Urbina,et al.  Comparative Efficacies of TAK-187, a Long-Lasting Ergosterol Biosynthesis Inhibitor, and Benznidazole in Preventing Cardiac Damage in a Murine Model of Chagas' Disease , 2005, Antimicrobial Agents and Chemotherapy.

[30]  D. N. Nicolaides,et al.  Reactions of furoxans with phosphorus ylides , 1986 .

[31]  N. Campillo,et al.  In vivo anti-Chagas vinylthio-, vinylsulfinyl-, and vinylsulfonylbenzofuroxan derivatives. , 2007, Journal of medicinal chemistry.

[32]  J. Berman.  Current treatment approaches to leishmaniasis , 2003, Current opinion in infectious diseases.

[33]  David S Hartsough,et al.  Development of alpha-keto-based inhibitors of cruzain, a cysteine protease implicated in Chagas disease. , 2005, Bioorganic & medicinal chemistry.

[34]  J. Aponte,et al.  Synthesis, cytotoxicity, and anti-Trypanosoma cruzi activity of new chalcones. , 2008, Journal of medicinal chemistry.

[35]  J. Turrens.  Oxidative stress and antioxidant defenses: a target for the treatment of diseases caused by parasitic protozoa. , 2004, Molecular aspects of medicine.

[36]  M. Chatterjee,et al.  Development of a modified MTT assay for screening antimonial resistant field isolates of Indian visceral leishmaniasis. , 2005, Parasitology international.

[37]  H. Cerecetto,et al.  ESR AND SPIN TRAPPING STUDIES OF TWO NEW POTENTIAL NTITRYPANOSOMAL DRUGS , 2003 .

[38]  É. Rosenthal,et al.  Recent understanding in the treatment of visceral leishmaniasis. , 2003, Journal of postgraduate medicine.

[39]  J. Périé,et al.  Trypanosoma cruzi: effect and mode of action of nitroimidazole and nitrofuran derivatives. , 2003, Biochemical pharmacology.

[40]  W. Colli,et al.  Trypanosoma cruzi: characterization of an intracellular epimastigote-like form. , 1999, Experimental parasitology.

[41]  J. Cazzulo,et al.  New trypanocidal hybrid compounds from the association of hydrazone moieties and benzofuroxan heterocycle. , 2008, Bioorganic & Medicinal Chemistry.

[42]  A. Teixeira,et al.  Evolution and pathology in chagas disease--a review. , 2006, Memorias do Instituto Oswaldo Cruz.

[43]  Thomas de Quincey.  [C] , 2000, The Works of Thomas De Quincey, Vol. 1: Writings, 1799–1820.

[44]  A. Merlino,et al.  Second generation of 5-ethenylbenzofuroxan derivatives as inhibitors of Trypanosoma cruzi growth: synthesis, biological evaluation, and structure-activity relationships. , 2007, Bioorganic & medicinal chemistry.

[45]  M. Haddadin,et al.  Reactions of benzofurazan oxide with amines—I : Reduction with diethylamine , 1979 .

[46]  A. Merlino,et al.  Development of a HPLC method for the determination of antichagasic phenylethenylbenzofuroxans and its major synthetic secondary products in the chemical production processes. , 2008, Journal of pharmaceutical and biomedical analysis.

[47]  F. Kierszenbaum.  Mechanisms of pathogenesis in Chagas disease , 2007, Acta Parasitologica.

[48]  F. Dörwald.  Organic Synthesis on Solid Phase , 2002 .

[49]  R. Gazzinelli,et al.  Molecular characterization of susceptible and naturally resistant strains of Trypanosoma cruzi to benznidazole and nifurtimox. , 1998, Molecular and biochemical parasitology.

[50]  A. Rojas de Arias,et al.  In vitro and in vivo antitrypanosomatid activity of 5-nitroindazoles. , 2009, European journal of medicinal chemistry.

[51]  Charette,et al.  Synthesis of a triphenylphosphine reagent on non-cross-linked polystyrene support: application to the Staudinger/Aza-wittig reaction , 2000, Organic letters.